Clinical Trial Update: PK of Rivaroxaban in Bariatric Patients - Extension [Phase 1]

View source ↗

Summary

A Phase 1 extension study reports the pharmacokinetics of rivaroxaban in bariatric patients to inform dosing for venous thromboembolism prophylaxis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Prophylaxis of Venous Thromboembolism | Phase 1 | Status: COMPLETED